Merck KGaA is in the investment-grade market Tuesday, a day after holding investor calls, to help fund its $3.9 billion ...

Immunome's varegacestat shows promising efficacy in desmoid tumors, with phase 3 topline data expected by 2025-end. Read why ...

Shares of SpringWorks Therapeutics SWTX have rallied 32.9% in the past three months compared with the industry’s increase of 2.7%. Here, we discuss the reasons for the same. Strong Launch of ...

SpringWorks has garnered interest from suitors thanks to its lead asset, Gomekli, which treats a rare genetic disorder that causes tumor growth in nerve tissue.

Shares of SpringWorks Therapeutics, Inc. SWTX have rallied 81% in the past three months compared with the industry’s increase of 15.9%. In November 2023, the FDA approved SpringWorks’ oral ...

BofA lowered the firm’s price target on SpringWorks Therapeutics (SWTX) to $55 from $58 and keeps a Buy rating on the shares. While political and rate uncertainty continues to be an overhang ...

SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for patients living with ...

SpringWorks is using Nirogacestat, while AbbVie provides ABBV-383. It is believed that Nirogacestat provides a boost for BCMA therapies like ABBV-383. This isn't the first partnership for SpringWorks.

SpringWorks launched last year with $103 million in financing, led by Bain Capital, OrbiMed Advisors and Pfizer Inc., and a plan to develop treatments for patients who lack good treatment options.